Show simple item record

dc.contributor.authorWang, H.
dc.contributor.authorBerger, K.N.
dc.contributor.authorMiller, E.L.
dc.contributor.authorFu, W.
dc.contributor.authorBroglie, L.
dc.contributor.authorGoldman, F.D.
dc.contributor.authorKonig, H.
dc.contributor.authorLim, S.J.
dc.contributor.authorBerg, A.S.
dc.contributor.authorTalano, J.-A.
dc.contributor.authorComito, M.A.
dc.contributor.authorFarag, S.S.
dc.contributor.authorPu, J.J.
dc.date.accessioned2024-08-06T03:50:18Z
dc.date.available2024-08-06T03:50:18Z
dc.date.issued2023-05-03
dc.identifier.citationWang H, Berger KN, Miller EL, et al. The impacts of total body irradiation on umbilical cord blood hematopoietic stem cell transplantation. Therapeutic Advances in Hematology. 2023;14. doi:10.1177/20406207231170708
dc.identifier.issn2040-6207
dc.identifier.doi10.1177/20406207231170708
dc.identifier.urihttp://hdl.handle.net/10150/673864
dc.description.abstractBackground: Umbilical cord blood hematopoietic stem cells are commonly used for hematopoietic system reconstitution in recipients after umbilical cord blood transplantation (UCBT). However, the optimal conditioning regimen for UCBT remains a topic of debate. The exact impact of total body irradiation (TBI) as a part of conditioning regimens remains unknown. Objectives: The aim of this study was to evaluate the impacts of TBI on UCBT outcomes. Design: This was a multi-institution retrospective study. Methods: A retrospective analysis was conducted on the outcomes of 136 patients receiving UCBT. Sixty-nine patients received myeloablative conditioning (MAC), in which 33 underwent TBI and 36 did not, and 67 patients received reduced-intensity conditioning (RIC), in which 43 underwent TBI and 24 did not. Univariate and multivariate analyses were conducted to compare the outcomes and the post-transplant complications between patients who did and did not undergo TBI in the MAC subgroup and RIC subgroup, respectively. Results: In the RIC subgroup, patients who underwent TBI had superior overall survival (adjusted hazard ratio [aHR] = 0.25, 95% confidence interval [CI]: 0.09–0.66, p = 0.005) and progression-free survival (aHR = 0.26, 95% CI: 0.10–0.66, p = 0.005). However, in the MAC subgroup, there were no statistically significant differences between those receiving and not receiving TBI. Conclusion: In the setting of RIC in UCBT, TBI utilization can improve overall survival and progression-free survival. However, TBI does not show superiority in the MAC setting. © The Author(s), 2023.
dc.language.isoen
dc.publisherSAGE Publications Ltd
dc.rights© The Author(s), 2023. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License.
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.subjectMyeloablative considition
dc.subjectpost cord blood hematological stem cell transplant outcome
dc.subjectreduced-intensity condition
dc.subjecttotal body irradiation
dc.subjectumbilical cord blood hematopoietic stem cell transplantation
dc.titleThe impacts of total body irradiation on umbilical cord blood hematopoietic stem cell transplantation
dc.typeArticle
dc.typetext
dc.contributor.departmentCancer Center, The University of Arizona
dc.identifier.journalTherapeutic Advances in Hematology
dc.description.noteOpen access journal
dc.description.collectioninformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.
dc.eprint.versionFinal Published Version
dc.source.journaltitleTherapeutic Advances in Hematology
refterms.dateFOA2024-08-06T03:50:19Z


Files in this item

Thumbnail
Name:
wang-et-al-2023.pdf
Size:
730.5Kb
Format:
PDF
Description:
Final Published Version

This item appears in the following Collection(s)

Show simple item record

© The Author(s), 2023.  This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License.
Except where otherwise noted, this item's license is described as © The Author(s), 2023. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License.